Kidney Therapeutics: Translating Discoveries into Prevention, Treatment and Cures for Kidney Diseases

项目总结至总体组成部分 尽管最近的发现解释了一些肾脏疾病的分子发病机制，但新的研究发现， 治疗方法出现得很慢。令人震惊的是，有3000万美国人患有肾脏疾病， 促进新治疗方法的开发存在迫切的未满足的需求。所提议的会议的总主题 西北乔治M.奥布莱恩肾脏核心中心命名为NU-GoKIDNEY，将专注于肾脏 治疗学-将发现转化为预防、治疗和治愈。为了实现这一目标， 多个科学和临床学科之间广泛而富有成效的合作， 传统互动。我们的中心将联合三个核心的研究人员：临床前模型核心 (Core治疗开发核心（核心B）和临床和转化核心（核心 C）。该中心将在西北大学培养独特的、无与伦比的人才来实现这一目标 目标，包括：1）一个特殊的跨学科肾脏研究者群体; 2）大量收集相关的 动物模型和细胞系; 3）世界领先的纳米医学研究所; 4）创新和世界一流的 化学系致力于药物发现; 5）世界领先的生物电子专业知识; 6）著名的 药物基因组学和药理学专家团队; 7）高水平的良好生产规范 (GMP)由核心主管之一开发的生产设施; 8）电子数据仓库，包括 670万个体患者与基因组数据相关联; 9）肾脏标本的大型生物储存库; 10）专业知识和 进行首次人体研究的基础设施; 11）社区参与进行 研究和12）创新和新企业办公室（INVO）。除了建立三个 生物医学核心，NU-GoKIDNEY中心将支持创新的富集计划和试点， 可行性研究旨在加强跨学科合作，吸引新的研究人员进入 肾脏疾病领域，并培养下一代肾脏创新者。一个在线门户网站肾枢纽将 提供访问这些独特的NU资源-第一次-到外面的世界和肾脏治疗 加速器将启动，以促进治疗创新和催化西北翻译 以及芝加哥全国和国际的肾脏社区。

PROJECT SUMMARY TO OVERALL COMPONENT Despite recent discoveries that explain the molecular pathogenesis of a number of kidney diseases, new therapies have been slow to emerge. With a staggering 30 million Americans suffering from kidney diseases, there is an urgent unmet need to facilitate development of new treatments. The overall theme of the proposed Northwestern George M. O’Brien Kidney Core Center named NU-GoKIDNEY, will focus on Kidney Therapeutics – to translate discoveries into prevention, treatment and cures. To realize this objective, requires extensive and productive collaborations between multiple scientific and clinical disciplines that do not traditionally interact. Our Center will unite investigators across three Cores: the Pre-Clinical Models Core (Core A), the Therapeutics Development Core (Core B) and the Clinical and Translational Core (Core C). The Center will nucleate unique, unparalleled talent available at Northwestern University to accomplish this goal, including: 1) an exceptional group of interdisciplinary kidney researchers; 2) large collection of relevant animal models and cell lines; 3) a world-leading nanomedicine institute; 4) an innovative and world-class chemistry department devoted to drug discovery; 5) world-leading bio-electronics expertise; 6) a renowned team of experts in pharmacogenomics and pharmacology; 7) a high level Good Manufacturing Practices (GMP) production facility developed by one of the core directors; 8) an electronic data warehouse comprising 6.7M individual patients linked to genomic data; 9) large biorepository of renal specimens; 10) expertise and infrastructure to conduct first-in-human studies; 11) track record of community engagement in the conduct of research and 12) an Innovation and New Ventures office (INVO). In addition to the establishment of the three biomedical cores, the NU-GoKIDNEY Center will support innovative Enrichment programs and Pilot and Feasibility studies designed to enhance cross-disciplinary collaborations, attract new investigators into the kidney diseases field and train the next generation of kidney innovators. An online portal nephro-HUB will provide access to these unique NU resources - for the first time - to the outside world and a Kidney Cure Accelerator will be launched to promote therapeutic innovation and catalyse translation within Northwestern and across the Chicagoland, national and international kidney communities.